Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in multiple myeloma

Bookmark and Share
Published: 11 Dec 2017
Views: 1830
Rating:
Save
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece

Prof Dimopoulos talks to ecancer at the 2017 ASH annual meeting about the POLLUX study looking at daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma. 

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.